Cat. #156566
Anti-RT1A (class I monomorphic) [OX18]
Cat. #: 156566
Unit size: 100 ug
Availability: 10-12 weeks
Target: RT1A (class I monomorphic)
Class: Monoclonal
Application: FACS ; IHC ; IP
Reactivity: Rat
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Medical Research Council; University of Oxford
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-RT1A (class I monomorphic) [OX18]
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Rat
- Host: Mouse
- Application: FACS ; IHC ; IP
- Description: The antibody is directed against Class I (RT-1A) histocompatibility antigens. It appears to be directed against non-polymorphic determinants. The antibody labels mature thymocytes.
- Immunogen: Rat spleen membrane glycoproteins depleted of Ia-A antigens
- Myeloma used: NS1
- Recommended controls: IgG1
Target Details
- Target: RT1A (class I monomorphic)
- Target background: The antibody is directed against Class I (RT-1A) histocompatibility antigens. It appears to be directed against non-polymorphic determinants. The antibody labels mature thymocytes.
Applications
- Application: FACS ; IHC ; IP
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Dry ice
References
- Fukumoto et al. 1982. Eur J Immunol. 12(3):237-43. PMID: 6178598.
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)
